Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
0.9000
0.00 (0.00%)
Jul 30, 2026, 1:01 PM EST
BCLI Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.02 | 0.03 | 0.19 | 1.3 | 0.77 | 18.86 |
Short-Term Investments | - | - | - | - | 2.21 | 3.24 |
Cash & Short-Term Investments | 0.02 | 0.03 | 0.19 | 1.3 | 2.98 | 22.09 |
Cash Growth | -99.09% | -84.49% | -85.61% | -56.42% | -86.50% | -47.32% |
Other Receivables | 0.12 | 0.09 | 0.06 | 0.05 | 0.09 | 0.09 |
Receivables | 0.12 | 0.09 | 0.06 | 0.05 | 0.09 | 0.09 |
Prepaid Expenses | 0.05 | 0.19 | 0.14 | 0.55 | 0.03 | 1.1 |
Total Current Assets | 0.18 | 0.31 | 0.39 | 1.9 | 3.11 | 23.28 |
Property, Plant & Equipment | 0.36 | 0.44 | 1.24 | 2.1 | 5.31 | 5.95 |
Other Intangible Assets | - | - | - | 0 | 0.01 | 0.02 |
Other Long-Term Assets | 0.22 | 0.27 | 0.21 | 0.21 | 0.02 | 0.03 |
Total Assets | 0.76 | 1.02 | 1.83 | 4.21 | 8.45 | 29.28 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 7.32 | 7.07 | 6.08 | 4.95 | 6.22 | 3.7 |
Accrued Expenses | 0.41 | 0.4 | 0.62 | 1.24 | 0.08 | 0.08 |
Short-Term Debt | 1.33 | 0.97 | 0.3 | - | - | - |
Current Portion of Leases | 0.16 | 0.21 | 0.55 | 0.6 | 1.43 | 1.46 |
Other Current Liabilities | 2.55 | 2.37 | 1.43 | 1 | 1.07 | 1.07 |
Total Current Liabilities | 11.76 | 11.01 | 8.98 | 7.8 | 8.8 | 6.32 |
Long-Term Leases | - | - | 0.17 | 0.67 | 2.67 | 3.62 |
Other Long-Term Liabilities | - | - | 0.45 | 0.59 | - | - |
Total Liabilities | 11.76 | 11.01 | 9.6 | 9.07 | 11.47 | 9.94 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 228.16 | 227.06 | 218.97 | 210.26 | 194.91 | 192.99 |
Retained Earnings | -239.07 | -236.94 | -226.64 | -215.01 | -197.82 | -173.54 |
Treasury Stock | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 | -0.12 |
Shareholders' Equity | -11.01 | -9.99 | -7.76 | -4.86 | -3.02 | 19.34 |
Total Liabilities & Equity | 0.76 | 1.02 | 1.83 | 4.21 | 8.45 | 29.28 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.49 | 1.18 | 1.02 | 1.28 | 4.09 | 5.08 |
Net Cash (Debt) | -1.47 | -1.15 | -0.83 | 0.03 | -1.11 | 17.02 |
Net Cash Growth | - | - | - | - | - | -50.99% |
Net Cash Per Share | -0.14 | -0.12 | -0.17 | 0.01 | -0.46 | 7.05 |
Filing Date Shares Outstanding | 11.03 | 11.03 | 6.52 | 4.56 | 2.45 | 2.43 |
Total Common Shares Outstanding | 11.03 | 11.03 | 6.14 | 4.03 | 2.45 | 2.43 |
Working Capital | -11.58 | -10.7 | -8.59 | -5.9 | -5.69 | 16.96 |
Book Value Per Share | -1.00 | -0.90 | -1.26 | -1.20 | -1.23 | 7.97 |
Tangible Book Value | -11.01 | -9.99 | -7.76 | -4.86 | -3.02 | 19.33 |
Tangible Book Value Per Share | -1.00 | -0.90 | -1.26 | -1.21 | -1.24 | 7.96 |
Machinery | - | 2.35 | 2.35 | 2.36 | 2.35 | 2.35 |
Leasehold Improvements | - | 0.84 | 0.84 | 0.84 | 0.84 | 0.81 |